Antidiabetic and antihyperlipidemic activity of asiatic acid in diabetic rats, role of HMG CoA: in vivo and in silico approaches.
Hyperlipidemia is an associated complication of diabetes and also a major risk factor for cardiovascular diseases. The present study was designed to examine the antihyperlipidemic effect of asiatic acid (AA) in streptozotocin (STZ) induced diabetic rats. Diabetes was induced in male Wistar rats by a single intraperitoneal injection of STZ (40 mg/kg b.w.). Diabetic rats show increased plasma glucose, total cholesterol, triglycerides, free fatty acids, phospholipids, low density lipoprotein, very low density liprotein, atherogenic index and decreased insulin and high density lipoprotein in diabetic rats. The activity of 3-hydroxy 3-methylglutaryl coenzyme A (HMG CoA) reductase increased significantly in contrast to the activities of lipoprotein lipase and lecithin cholesterol acyltransferase. In addition, the molecular docking of AA against HMG CoA reductase involved in cholesterol biosynthesis using Argus software. Diabetic rats were treated with AA shifted all these parameters towards normalcy. AA has shown best ligand binding energy 11.8122 kcal/mol. The antihyperlipidemic effect of AA was compared with glibenclamide; a well-known antihyperglycemic drug. In conclusion, this study indicates that AA showed an antihyperlipidemic effect in addition to its antidiabetic effect in experimental diabetes.
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar 608002, India.
Vinayagam
V
Ramachandran
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar 608002, India. Electronic address: jayamsaranbio@gmail.com.
Ramalingam
R
Saravanan
Department of Zoology, Faculty of Science, Annamalai University, Annamalainagar 608002, India.
Poomalai
P
Senthilraja
D000214:Acyl Coenzyme A / Q000378:metabolism*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D028041:Centella / Q000737:chemistry; D002784:Cholesterol / Q000096:biosynthesis* / Q000097:blood; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D005905:Glyburide / Q000494:pharmacology / Q000627:therapeutic use; D025782:Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent / Q000378:metabolism; D006949:Hyperlipidemias / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D053978:Pentacyclic Triterpenes / Q000494:pharmacology / Q000627:therapeutic use*; D008517:Phytotherapy; D010936:Plant Extracts / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood
D000214:Acyl Coenzyme A; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D053978:Pentacyclic Triterpenes; D010936:Plant Extracts; D014280:Triglycerides; C008047:3-hydroxy-3-methylglutaryl-coenzyme A; D002784:Cholesterol; C017032:asiatic acid; D025782:Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; D005905:Glyburide
Antihyperlipidemic; Asiatic acid; Diabetes mellitus; HMG CoA reductase; Streptozotocin